Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Open access
Ghosh, Ritwik, Narasanna, Archana, Wang, Shizhen Emily, Liu, Shuying, Chakrabarty, Anindita, Balko, Justin M., González-Angulo, Ana María, Mills, Gordon B., Penuel, Elicia, Winslow, John, Sperinde, Jeff, Dua, Rajiv, Pidaparthi, Sailaja, Mukherjee, Ali, Leitzel, Kim, Kostler, Wolfgang J., Lipton, Allan, Bates, Michael, Arteaga, Carlos L. · 2011 · Cancer Research

Abstract

In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cell surface as monomers, homodimers, and heterodimers with EGFR/HER3. The therapeutic antibody trastuzumab, an approved therapy for HER2+ breast cancer, cannot block ligand-induced HER2 heterodimers, suggesting it cannot effectively inhibit HER2 signaling. Hence, HER2 oligomeric states may predict the odds of a clinical response to trastuzumab in HER2-driven tumors. To test this hypothesis, we generated nontransformed human MCF10A mammary epithelial cells stably expressing a chimeric HER2–FKBP molecule that could be conditionally induced to homodimerize by adding the FKBP ligand AP1510, or instead induced to heterodimerize with EGFR or HER3 by adding the heterodimer ligands EGF/TGFα or heregulin. AP1510, EGF, and heregulin each induced growth of MCF10A cells expressing HER2–FKBP. Trastuzumab inhibited homodimer-mediated but not heterodimer-mediated cell growth. In contrast, the HER2 antibody pertuzumab, which blocks HER2 heterodimerization, inhibited growth induced by heregulin but not AP1510. Lastly, the HER2/EGFR tyrosine kinase inhibitor lapatinib blocked both homodimer- and heterodimer-induced growth. AP1510 triggered phosphorylation of Erk1/2 but not AKT, whereas trastuzumab inhibited AP1510-induced Erk1/2 phosphorylation and Shc-HER2 homodimer binding, but not TGFα-induced AKT phosphorylation. Consistent with these observations, high levels of HER2 homodimers correlated with longer time to progression following trastuzumab therapy in a cohort of patients with HER2-overexpressing breast cancer. Together, our findings confirm the notion that HER2 oligomeric states regulate HER2 signaling, also arguing that trastuzumab sensitivity of homodimers may reflect their inability to activate the PI3K (phosphoinositide 3-kinase)/AKT pathway. A clinical implication of our results is that high levels of HER2 homodimers may predict a positive response to trastuzumab. Cancer Res; 71(5); 1871–82. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-1872

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 228

Metadata

Authors
Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., González-Angulo, A. M., Mills, G. B., Penuel, E., Winslow, J., Sperinde, J., Dua, R., Pidaparthi, S., Mukherjee, A., Leitzel, K., Kostler, W. J., Lipton, A., Bates, M., & Arteaga, C. L.
Venue
Cancer Research
Published
2011-03-01
Volume
71
Issue
5
Pages
1871-1882
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2129750399
Cited by
228
References
6
FWCI
10.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-1872
The paper
Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., González-Angulo, A. M., Mills, G. B., Penuel, E., Winslow, J., Sperinde, J., Dua, R., Pidaparthi, S., Mukherjee, A., Leitzel, K., Kostler, W. J., Lipton, A., Bates, M., & Arteaga, C. L. (2011). Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-1872

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.